Trial · NCT00414167
Craving, Binge Eating and Obesity
NCT00414167, Phase 2, Phase 3, Completed, Yale University; results first posted 2014-03-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Craving, Binge Eating and Obesity. Trials, record NCT00414167. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00414167
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Craving, Binge Eating and Obesity
- NCT number
- NCT00414167
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 61 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Binge Eating Disorder, Obesity
- Interventions
- bupropion, Placebo
- First posted
- 2006-12-21
- Last updated
- 2020-04-03
- Results first posted
- 2014-03-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Binge Eating Episodes | One week (at post treatment) | |
| Secondary | Percent BMI Loss | 8 weeks (baseline and 8 weeks) | Percent loss in Body Mass Index |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Frequency of Binge Eating Episodes | One week (at post treatment) | Baseline forward imputation for missing data. | episodes/week | MEAN |
| SECONDARY | Percent BMI Loss | 8 weeks (baseline and 8 weeks) | Baseline values imputed forward for missing data. | Percent loss | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Frequency of Binge Eating Episodes | Bupropion | 0.8 | Standard Deviation 1.2 | episodes/week | |
| Frequency of Binge Eating Episodes | Placebo | 1.0 | Standard Deviation 1.5 | episodes/week | |
| Percent BMI Loss | Bupropion | 1.8 | Standard Deviation 2.6 | Percent loss | |
| Percent BMI Loss | Placebo | 0.6 | Standard Deviation 2.1 | Percent loss |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bupropion (300 mg/d) | 31 | |
| Overall Study | STARTED | Placebo | 30 | |
| Overall Study | COMPLETED | Bupropion (300 mg/d) | 27 | |
| Overall Study | COMPLETED | Placebo | 27 | |
| Overall Study | NOT COMPLETED | Bupropion (300 mg/d) | 4 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bupropion | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Bupropion | 0 | 31 |
| Total, other adverse events | Placebo | 0 | 30 |
| Total, serious adverse events | Bupropion | 0 | 31 |
| Total, serious adverse events | Placebo | 0 | 30 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23656848 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23DK071646 | Craving, Binge Eating, and Obesity | WHITE, MARNEY A | YALE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2005 to 2009 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bupropion vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00414167
GET https://conductscience.org/api/trials/v1/NCT00414167/registered